Under phase I/II clinical trials targeting the small molecule PORCN that is required for Wnt ligand-receptor activation. Treats metastatic CRC, pancreatic, breast, HNSCC, esophageal, lung, and cervical cancers. Here, PORCN is linked to cervical carcinoma.